Nanoparticulate systems for brain delivery of drugs

Advanced Drug Delivery Reviews

Volumn 47, Issue 1, 2001, Pages 65-81

  Kreuter, Jörg ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Blood brain barrier; Brain tumors; Drug delivery to the brain; Glioblastomas; Nanoparticles

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; APOLIPOPROTEIN E; CENTRAL NERVOUS SYSTEM AGENTS; CREMOPHOR; CREMOPHOR EZ; CREMOPOHOR EZ; DIPEPTIDE DERIVATIVE; DOXORUBICIN; GLYCOPROTEIN P; KYTORPHIN; LEUCINE ENKEPHALIN[2 DEXTRO ALANINE]; LOPERAMIDE; LOW DENSITY LIPOPROTEIN RECEPTOR; MRZ 2576; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NALOXONE; NANOPARTICLE; NEUROPEPTIDE; POLIDOCANOL; POLOXAMER; POLOXAMINE 908; POLY(BUTYL 2 CYANOACRYLATE); POLYSORBATE 20; POLYSORBATE 40; POLYSORBATE 60; POLYSORBATE 80; POLYSORBATE 85; PROBENECID; SURFACTANT; TUBOCURARINE CHLORIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BLOOD BRAIN BARRIER; BRAIN; BRAIN CAPILLARY; BRAIN TUMOR; DRUG ADSORPTION; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG RELEASE; DRUG TRANSPORT; ENDOCYTOSIS; ENDOTHELIUM CELL; GLIOBLASTOMA; NONHUMAN; PLASMA; PRIORITY JOURNAL; REVIEW; TIGHT JUNCTION; TRANSCYTOSIS;

EID: 0035937595     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(00)00122-8     Document Type: Article

References (63)

1. Do ultra-low frequency (ULF) magnetic fields affect the blood-brain barrier
2. The blood-brain barrier: Principles for targeting peptides and drugs to the central nervous system
3. Ultrastructure of the brain endothelium
4. Drug entry into the brain and its pharmacologic manipulation
5. Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo
6. Targeted delivery of DANN by liposomes and polymers
7. Biodistribution of calcitonin encapsulated in liposomes in mice with particular reference to the central nervous system
8. Brain drug delivery of small molecules using immunoliposomes
9. Modulation of the blood-brain barrier permeability
10. A new function for the LDL receptor: Transcytosis of LDL across the blood-brain barrier
11. Nanoparticles
12. Pharmacokinetics and distribution of a biodegradable drug-carrier
13. Biodegradable polymeric nanoparticles and drug carriers for antitumor agents
14. Analgesic activity of the hexapeptide dalargin adsorbed on the surface of polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles
15. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles)
16. Nanoparticles, a drug carrier system to pass the blood-brain barrier, permit central analgesic effects of i.v. dalargin injections
17. Circadian phase-dependent antinociceptive reaction in mice after i.v. injection of dalargin-loaded nanoparticles determined by the hot-plate test and the tail-flick test
18. Nanoparticle technology for delivery of drugs across the blood-brain barrier
19. Efficacy of oral dalargin-loaded nanopartcle delivery across the blood-brain barrier
20. Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity
21. Genetic differences in daily rhythms of pain sensitivity in mice
22. Influence of the type of surfactant on the analgesic effects induced by the peptide dalargin after its delivery across the blood-brain barrier using surfactant-coated nanoparticles
23. Hyperalgesia induced by naloxone follows diurnal rhythm in responsitivity to painful stimuli
24. 3H-labelled dalargin bound to poly(butyl cyanoacrylate nanoparticles) after i.v. injections to mice
25. Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles
26. Significant entry of tubocurarine into the brain of rats by absorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: An in situ brain perfusion study
27. Enhancement of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcyanoacylate) nanoparticles as a parenteral controlled release delivery system
28. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles
29. Effect of the nonionic surfactant poloxamer 338 on the fate and deposition of polystyrene microspheres following intravenous administration
30. The organ distribution and circulation time of intravenously injected colloidal carriers sterically stabilized with a blockcopolymer-poloxamine 908
31. Modification of the body distribution of poly(methyl methacrylate) nanoparticles in rats by coating with surfactants
32. Toxicity of polyalkylcyanoacrylate nanoparticles II: Doxorubicin-loaded nanoparticles
33. Chemotherapy of brain tumours using doxorubicin bound to polysorbate 80-coated nanoparticles
34. Enhanced brain tumor selectivity of cationic magnetic polysaccharide microspheres
35. Uptake of surfactant-coated poly(methyl methacrylate)-nanoparticles by bovine brain microvessel endothelial cell monolayers
36. Interaction of poly-(butylcyanoacrylate) nanoparticles with the blood-brain barrier in vivo and in vitro
37. Polysorbate 80-coating enhances uptake of polybutylcyanoacrylate (PBCA)-nanoparticles by human, bovine and murine primary brain capilary endothelial cells
38. The influence of polysorbate 80-coated nanoparticles on bovine brain capillary endothelial cells in vitro
39. An easier, reproducible, and mass-production method to study the blood brain barrier in vitro
40. Drug transfer across the blood-brain barrier: Correlation between in vitro and in vivo models
41. Evaluation of effect of charge and lipid coating on ability of 60-nm nanoparticles to cross an in vitro model of the blood-brain barrier
42. 14C in the rat
43. The exchange of materials between cerebrospinal fluid and brain
44. Spinal subarachnoid perfusion of rhesus monkeys
45. Regional brain blood low, blood volume, and haematocrit values the adult rat
46. Structural and functional variations in capillary systems within the brain
47. Low-density lipoprotein receptor on endothelium of brain capillaries
48. Characterization of the scavenger receptor on bovine cerebral endothelial cells in vitro
49. Upregulation of the low density lipoprotein receptor at the blood-brain barrier: Intercommunications between brain capillary endothelial cells and astrocytes
50. Expression of receptors for native and chemically modified low-density lipoproteins in brain microvessels
51. Receptor-mediated transcytosis of blood-borne molecules through blood-brain barrier endothelial cells: Drug targeting by endogenous transport routes
52. Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins
53. Reversal of multidrug resistance by surfactants
54. The use of surfactants to enhance the permeability of peptides through Caco-2 cells by inhibition of an apically polarized efflux system
55. Multidrug resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites
56. Phase I clinical trial and pharmacokinetic evaluation of doxorubicin carried by poly(isohexyl cyanoacrylate) nanoparticles